Research
Hormonal
Anti-inflammatory therapies targeting specific pathways (e.g., IKKbeta/NF-kB inhibition with salicylate, IL-1 blockade with anakinra) can improve glycemic control and insulin sensitivity in patients with type 2 diabetes.
While not a lifestyle intervention, research shows that reducing specific inflammatory pathways (like IKKbeta/NF-kB) can improve blood sugar control in diabetes. This highlights the importance of inflammation in metabolic disease.
GoodSupportsMEDIUM confidence
Salsalate, a prodrug of salicylate, can attenuate IKKbeta/NF-kB activity and has been shown to improve glycemic control in patients with type 2 diabetes... IL-1 receptor antagonists (anakinra) improve glycemia and beta cell function and decrease systemic inflammatory markers
Why this rating
Based on clinical trials and preclinical studies, though some TNF-alpha blockade failed.
Source
Inflammatory links between obesity and metabolic disease
Carey N. Lumeng et al. · Journal of Clinical Investigation · 2011
DOI 10.1172/jci57132
narrative_reviewCited 2,256×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity induces a chronic, low-grade inflammatory state termed 'metainflammation' characterized by the accumulation of proinflammatory M1 macrophages in adipose tissue, which directly impairs insulin signaling and contributes to systemic insulin resistance and type 2 diabetes.Strong
- Activation of Toll-like receptor 4 (TLR4) by saturated free fatty acids is a primary mechanism linking nutrient excess to inflammation and insulin resistance in metabolic tissues.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →